CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim safety analysis
DOI 10.1055/s-2004-831656
Bibliografische Angaben
Nachweis in CareLit
Autor:innenHT Arkenau, HJ Schmoll, S Kubicka, T Seufferlein, P Reichardt, W Freier, U Graeven, A Grothey, R Porschen
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2004
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: In a previous phase III study the FUFOX regimen has shown superior response rates than bolus 5-FU/FA (Mayo Clinic protocol) in patients with. The combination of capecitabine (CAP) and oxaliplatin (OX) has demonstrated good efficacy and safety results in recent phase II studies. In August 2002 we initiated a phase III trial to compare FUFOX and CAPOX as first line therapy in patients with ACRC. Here, we present…
Zitieren
Zitierempfehlung
HT Arkenau, HJ Schmoll, S Kubicka, T Seufferlein, P Reichardt, W Freier, U Graeven, A Grothey, R Porschen (2004) Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim safety analysis. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-2004-831656
Mit CareLit weiterarbeiten